January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

57

Dr. Rudy Tanzi - How to SHIELD the Brain (part 2)

Join us for part 2 of BrainStorm’s interview with Dr.

LISTEN NOW
56

Dr. Rudy Tanzi – How to SHIELD the Brain (part 1)

Brain health and lifestyle interventions play an important role in longevity.  Dr.

LISTEN NOW
55

George Vradenburg - Advancing the Science of Alzheimer’s Prevention (part 2)

Breakthrough advances in research coupled with health-conscious strategies around brain health continue to bring us closer to the prevention of Alz

LISTEN NOW